Programmed cell death protein 1 (PD-1) is an inhibitory receptor that is expressed on some tumor cells and causes down regulation of the immune system by reducing T-cell activity. PD-1 inhibitors are a group of proteins that block the activity of PD-1 and PDL1 immune checkpoint.
PD-1 and PD-L1 Inhibitors Market contains market size and forecasts of PD-1 and PD-L1 Inhibitors in global, including the following market information:
- Global PD-1 and PD-L1 Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global PD-1 and PD-L1 Inhibitors Market Sales, 2017-2022, 2023-2028, (Tons)
- Global top five PD-1 and PD-L1 Inhibitors companies in 2021 (%)
The global PD-1 and PD-L1 Inhibitors market was valued at 40690 million in 2021 and is projected to reach US$ 140220 million by 2028, at a CAGR of 19.3% during the forecast period.
- The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
- Humanized IgG1(Immunoglobulin 1) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
- The global key manufacturers of PD-1 and PD-L1 Inhibitors include Merck, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Regeneron Pharmaceuticals, Eli Lilly and Company, Roche Genetech, AstraZeneca and Jiangsu HengRui Medicine Co., Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
- We surveyed the PD-1 and PD-L1 Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PD-1 and PD-L1 Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global PD-1 and PD-L1 Inhibitors Market Segment Percentages, by Type, 2021 (%)
- Humanized IgG1(Immunoglobulin 1)
- Humanized IgG4(Immunoglobulin 5)
- Cytokine
Global PD-1 and PD-L1 Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global PD-1 and PD-L1 Inhibitors Market Segment Percentages, by Application, 2021 (%)
- Oral
- Subcutaneous Injection
Global PD-1 and PD-L1 Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global PD-1 and PD-L1 Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies PD-1 and PD-L1 Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies PD-1 and PD-L1 Inhibitors revenues share in global market, 2021 (%)
- Key companies PD-1 and PD-L1 Inhibitors sales in global market, 2017-2022 (Estimated), (Tons)
- Key companies PD-1 and PD-L1 Inhibitors sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Merck
- Novartis
- Bristol-Myers Squibb
- GlaxoSmithKline
- Regeneron Pharmaceuticals
- Eli Lilly and Company
- Roche Genetech
- AstraZeneca
- Jiangsu HengRui Medicine Co., Ltd.
- Curis Inc.
- Aurigene
Industry Market Size
